Lincoln, Nebraska, May 25, 2023 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, July 14, 2023, to shareholders of record as of the close of business on Friday, June 30, 2023.
For more than 40 years, NRC Health has been committed to achieving Human Understanding and bringing healthcare organizations closer to their customers than ever before by illuminating and improving the key moments that define an experience and build trust. Guided by their uniquely empathic heritage, proprietary methods, skilled associates, and holistic approach, NRC Health helps its customers design experiences that exceed expectations, inspire loyalty, and improve well-being among patients, residents, physicians, nurses, and staff.
| Last Trade: | US$11.77 |
| Daily Change: | 0.09 0.77 |
| Daily Volume: | 58,815 |
| Market Cap: | US$271.420M |
July 28, 2025 April 28, 2025 February 25, 2025 January 27, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
